Skip to main content

Table 1 Estimated prices of agents approved to treat prostate cancer

From: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Treatment

Cost of treatment alonea

Median overall survival benefit

sipuleucel-T

$93,000 (median 3 cycles)

25.8 months vs. 21.7 months [9]

enzalutamide

$89,952 (median of 8 cycles)

18.4 months vs. 13.6 months [4]

abiraterone

$144,950 (median of 14 cycles)

34.7 vs. 30.3 months [6, 59]

docetaxel

$25,000 (median of 10 cycles)

18.9 months vs. 16.5 months [60]

cabazitaxel

$68,751 (median of 6 cycles)

15.1 months vs. 12.7 months [7]

radium-223

$155,048 (median of 6 injections)

14.9 months vs. 11.3 months [8]

  1. aAs determined by using estimates of average wholesale drug prices retrieved from UptoDate accessed 11/17/2016